A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells: A pilot study in prostate cancer patients

• J. L. García ^[1] ; R. Lozano ^[2] ; I. Misiewicz-Krzeminska ^[1] ; J. Fernández-Mateos ^[2] ; P. Krzeminski ^[1] ; S. Alfonso ^[2] ; R. A. Marcos ^[4] ; R. García ^[2] ; F. Gómez-Veiga ^[2] ; Á. Virseda ^[2] ; M. Herrero ^[2] ; D. Olmos ^[3] ; J. J. Cruz-Hernández ^[2]
  1. [1] Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer

     Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer

     Salamanca, España

     
  2. [2] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  3. [3] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  4. [4] Complejo Asistencial Nuestra Señora de Sonsoles, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 11 (November 2017), 2017, págs. 1350-1357
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients.

    Methods Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified.

    Results The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p < 0.05). CD133 was expressed in 69 (96%) patients. The median CD133+ expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133+ captured cells were performed: 37 cases showed ≥four CD133+ CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN: 70% were ARV-7 positive vs. 67%, which were AR-V7 negative.

    Conclusions Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.